Revenue Breakdown
Composition ()
No data
Revenue Streams
Ernexa Therapeutics Inc (ERNA) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Subscription revenue, accounting for 93.9% of total sales, equivalent to $1.10M. Other significant revenue streams include Other revenue and Hardware revenue. Understanding this composition is critical for investors evaluating how ERNA navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Comparative Benchmarking
In the context of the broader market, ERNA competes directly with industry leaders such as PULM and ALZN. With a market capitalization of $9.54M, it holds a significant position in the sector. When comparing efficiency, ERNA's gross margin of N/A stands against PULM's N/A and ALZN's N/A. Such benchmarking helps identify whether Ernexa Therapeutics Inc is trading at a premium or discount relative to its financial performance.
